{"success":true,"data":{"pressRelease":{"id":"18880","rtpr_id":"nGNX7SBl15","ticker":"PRQR","exchange":"NASDAQ","all_tickers":["PRQR"],"title":"ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026","author":"Globe Newswire","published_at":"2026-05-04T12:00:00.953Z","article_body":"LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR\nTherapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated\nto changing lives through transformative RNA therapies based on its\nproprietary Axiomer™ RNA editing technology platform, today announced the\nAnnual General Meeting (AGM) of Shareholders will take place on Tuesday, June\n2, 2026 at 1500 CEST at the offices of Allen Overy Shearman Sterling LLP, in\nAmsterdam, the Netherlands.\n\nAll relevant documents and information for the meeting, including the notice\nand agenda and explanatory notes, are or will be made available in the\n“Investors & Media” section of ProQR’s website (www.proqr.com) under\n“Financials and filings” and then “Shareholder meeting”. The documents\nwill also be made available on the SEC’s website at www.sec.gov.\nShareholders that wish to attend should register as described in the notice\nand agenda.\n\nAbout Axiomer(™)\n\nProQR is pioneering a next-generation RNA base editing technology called\nAxiomer(™), which could potentially yield a new class of medicines for\ndiverse types of diseases. Axiomer(™) “Editing Oligonucleotides”, or\nEONs, mediate single nucleotide changes to RNA in a highly specific and\ntargeted way using molecular machinery that is present in human cells called\nADAR (Adenosine Deaminase Acting on RNA). Axiomer(™) EONs are designed to\nrecruit and direct endogenously expressed ADARs to change an Adenosine (A) to\nan Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) –\ncorrecting an RNA with a disease-causing mutation back to a normal (wild type)\nRNA, modulating protein expression, or altering a protein so that it will have\na new function that helps prevent or treat disease.\n\nAbout ProQR\n\nProQR Therapeutics is dedicated to changing lives through the creation of\ntransformative RNA therapies. ProQR is pioneering a next-generation RNA\ntechnology called Axiomer(™), which uses a cell’s own editing machinery\ncalled ADAR to make specific single nucleotide edits in RNA to reverse a\nmutation or modulate protein expression and could potentially yield a new\nclass of medicines for both rare and prevalent diseases with unmet need. Based\non our unique proprietary RNA repair platform technologies we are growing our\npipeline with patients and loved ones in mind.\n\nLearn more about ProQR at www.proqr.com.\n\nForward Looking Statements\n\nThis press release contains forward-looking statements. All statements other\nthan statements of historical fact are forward-looking statements, which are\noften indicated by terms such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\"\n\"expect,\" \"goal,\" \"intend,\" \"look forward to\", \"may,\" \"plan,\" \"potential,\"\n\"predict,\" \"project,\" \"should,\" \"will,\" \"would\" and similar expressions. Such\nforward-looking statements include, but are not limited to, statements\nregarding the location and time of the AGM and the availability of all\nrelevant documents and information, our business, technology, strategy, our\nAxiomer platform and pipeline, including the continued development and\nadvancement of our Axiomer platform and pipeline, the therapeutic potential of\nour Axiomer RNA editing oligonucleotides, and the potential of our\ntechnologies and product candidates. Forward-looking statements are based on\nmanagement's beliefs and assumptions and on information available to\nmanagement only as of the date of this press release. Our actual results could\ndiffer materially from those anticipated in these forward-looking statements\nfor many reasons, including, without limitation, the risks, uncertainties and\nother factors in our filings made with the Securities and Exchange Commission,\nincluding certain sections of our most recent annual report filed on Form\n20-F. These risks and uncertainties include, among others, the cost, timing\nand results of preclinical studies and clinical trials and other development\nactivities by us and our collaborative partners whose operations and\nactivities may be slowed or halted shortage and pressure on supply and\nlogistics on the global market, economic sanctions and international tariffs;\nthe likelihood of our preclinical and clinical programs being initiated and\nexecuted on timelines provided and reliance on our contract research\norganizations and predictability of timely enrollment of subjects and patients\nto advance our clinical trials and maintain their own operations; our reliance\non contract manufacturers to supply materials for research and development and\nthe risk of supply interruption from a contract manufacturer; the potential\nfor future data to alter initial and preliminary results of early-stage\nclinical trials; the unpredictability of the duration and results of the\nregulatory review of applications or clearances that are necessary to initiate\nand continue to advance and progress our clinical programs; the ability to\nsecure, maintain and realize the intended benefits of collaborations with\npartners, including the collaboration with Lilly; the possible impairment of,\ninability to obtain, and costs to obtain intellectual property rights;\npossible safety or efficacy concerns that could emerge as new data are\ngenerated in research and development; general business, operational,\nfinancial and accounting risks, and risks related to litigation and disputes\nwith third parties; and risks related to macroeconomic conditions and market\nvolatility resulting from global economic developments, geopolitical events\nand conflicts, high inflation, rising interest rates, tariffs and potential\nfor significant changes in U.S. policies and regulatory environment. Given\nthese risks, uncertainties and other factors, you should not place undue\nreliance on these forward-looking statements, and we assume no obligation to\nupdate these forward-looking statements, even if new information becomes\navailable in the future, except as required by law.\n\nFor ProQR Therapeutics N.V.\n\nInvestor and media contact:\nSarah Kiely\nProQR Therapeutics N.V.\nT: +1 617 599 6228\nskiely@proqr.com\nor\nInvestor contact:\nPeter Kelleher\nLifeSci Advisors\nT: +1 617 430 7579 \npkelleher@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f5ae7794-bff7-44dc-8709-0e9c3a9eac77)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7SBl15","title":"ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026","author":"Globe Newswire","ticker":"PRQR","created":"2026-05-04T12:00:00.953Z","tickers":["PRQR"],"exchange":"NASDAQ","article_body":"LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR\nTherapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated\nto changing lives through transformative RNA therapies based on its\nproprietary Axiomer™ RNA editing technology platform, today announced the\nAnnual General Meeting (AGM) of Shareholders will take place on Tuesday, June\n2, 2026 at 1500 CEST at the offices of Allen Overy Shearman Sterling LLP, in\nAmsterdam, the Netherlands.\n\nAll relevant documents and information for the meeting, including the notice\nand agenda and explanatory notes, are or will be made available in the\n“Investors & Media” section of ProQR’s website (www.proqr.com) under\n“Financials and filings” and then “Shareholder meeting”. The documents\nwill also be made available on the SEC’s website at www.sec.gov.\nShareholders that wish to attend should register as described in the notice\nand agenda.\n\nAbout Axiomer(™)\n\nProQR is pioneering a next-generation RNA base editing technology called\nAxiomer(™), which could potentially yield a new class of medicines for\ndiverse types of diseases. Axiomer(™) “Editing Oligonucleotides”, or\nEONs, mediate single nucleotide changes to RNA in a highly specific and\ntargeted way using molecular machinery that is present in human cells called\nADAR (Adenosine Deaminase Acting on RNA). Axiomer(™) EONs are designed to\nrecruit and direct endogenously expressed ADARs to change an Adenosine (A) to\nan Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) –\ncorrecting an RNA with a disease-causing mutation back to a normal (wild type)\nRNA, modulating protein expression, or altering a protein so that it will have\na new function that helps prevent or treat disease.\n\nAbout ProQR\n\nProQR Therapeutics is dedicated to changing lives through the creation of\ntransformative RNA therapies. ProQR is pioneering a next-generation RNA\ntechnology called Axiomer(™), which uses a cell’s own editing machinery\ncalled ADAR to make specific single nucleotide edits in RNA to reverse a\nmutation or modulate protein expression and could potentially yield a new\nclass of medicines for both rare and prevalent diseases with unmet need. Based\non our unique proprietary RNA repair platform technologies we are growing our\npipeline with patients and loved ones in mind.\n\nLearn more about ProQR at www.proqr.com.\n\nForward Looking Statements\n\nThis press release contains forward-looking statements. All statements other\nthan statements of historical fact are forward-looking statements, which are\noften indicated by terms such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\"\n\"expect,\" \"goal,\" \"intend,\" \"look forward to\", \"may,\" \"plan,\" \"potential,\"\n\"predict,\" \"project,\" \"should,\" \"will,\" \"would\" and similar expressions. Such\nforward-looking statements include, but are not limited to, statements\nregarding the location and time of the AGM and the availability of all\nrelevant documents and information, our business, technology, strategy, our\nAxiomer platform and pipeline, including the continued development and\nadvancement of our Axiomer platform and pipeline, the therapeutic potential of\nour Axiomer RNA editing oligonucleotides, and the potential of our\ntechnologies and product candidates. Forward-looking statements are based on\nmanagement's beliefs and assumptions and on information available to\nmanagement only as of the date of this press release. Our actual results could\ndiffer materially from those anticipated in these forward-looking statements\nfor many reasons, including, without limitation, the risks, uncertainties and\nother factors in our filings made with the Securities and Exchange Commission,\nincluding certain sections of our most recent annual report filed on Form\n20-F. These risks and uncertainties include, among others, the cost, timing\nand results of preclinical studies and clinical trials and other development\nactivities by us and our collaborative partners whose operations and\nactivities may be slowed or halted shortage and pressure on supply and\nlogistics on the global market, economic sanctions and international tariffs;\nthe likelihood of our preclinical and clinical programs being initiated and\nexecuted on timelines provided and reliance on our contract research\norganizations and predictability of timely enrollment of subjects and patients\nto advance our clinical trials and maintain their own operations; our reliance\non contract manufacturers to supply materials for research and development and\nthe risk of supply interruption from a contract manufacturer; the potential\nfor future data to alter initial and preliminary results of early-stage\nclinical trials; the unpredictability of the duration and results of the\nregulatory review of applications or clearances that are necessary to initiate\nand continue to advance and progress our clinical programs; the ability to\nsecure, maintain and realize the intended benefits of collaborations with\npartners, including the collaboration with Lilly; the possible impairment of,\ninability to obtain, and costs to obtain intellectual property rights;\npossible safety or efficacy concerns that could emerge as new data are\ngenerated in research and development; general business, operational,\nfinancial and accounting risks, and risks related to litigation and disputes\nwith third parties; and risks related to macroeconomic conditions and market\nvolatility resulting from global economic developments, geopolitical events\nand conflicts, high inflation, rising interest rates, tariffs and potential\nfor significant changes in U.S. policies and regulatory environment. Given\nthese risks, uncertainties and other factors, you should not place undue\nreliance on these forward-looking statements, and we assume no obligation to\nupdate these forward-looking statements, even if new information becomes\navailable in the future, except as required by law.\n\nFor ProQR Therapeutics N.V.\n\nInvestor and media contact:\nSarah Kiely\nProQR Therapeutics N.V.\nT: +1 617 599 6228\nskiely@proqr.com\nor\nInvestor contact:\nPeter Kelleher\nLifeSci Advisors\nT: +1 617 430 7579 \npkelleher@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f5ae7794-bff7-44dc-8709-0e9c3a9eac77)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-04T12:00:01.041062019Z","server_sent_at_ms":1777896001041},"received_at":"2026-05-04T12:00:01.099Z","source_url":"https://www.globenewswire.com/news-release/2023/05/16/2669816/33039/en/proqr-announces-first-quarter-2023-operating-and-financial-results.html"},"analysis":{"id":"13689","press_release_id":"18880","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"ProQR Therapeutics announced its Annual General Meeting of Shareholders will be held on June 2, 2026, at 1500 CEST in Amsterdam.\n\nRelevant documents, including the notice and agenda, will be available on the company's website and the SEC's website.\n\nThe company reiterated its focus on its Axiomer RNA editing technology platform.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine AGM announcement; no material news."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Sarah Kiely","role":"Investor and media contact"},{"name":"Peter Kelleher","role":"Investor contact"}],"products":["Axiomer™","Editing Oligonucleotides","EONs"],"companies":[{"name":"Allen Overy Shearman Sterling LLP","relationship":"meeting venue"},{"name":"LifeSci Advisors","relationship":"investor relations firm"},{"name":"ProQR Therapeutics N.V.","ticker":"PRQR"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of an Annual General Meeting of Shareholders with no material news, votes, or special items disclosed."},"tickerRelevance":{"others":[],"primary":"PRQR"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/mid-cap","eventGravity":"routine_annual_meeting","householdBrandBoost":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"ProQR Therapeutics announced its Annual General Meeting of Shareholders will be held on June 2, 2026, at 1500 CEST in Amsterdam.\n\nRelevant documents, including the notice and agenda, will be available on the company's website and the SEC's website.\n\nThe company reiterated its focus on its Axiomer RNA editing technology platform.","key_figures":{},"named_entities":{"people":[{"name":"Sarah Kiely","role":"Investor and media contact"},{"name":"Peter Kelleher","role":"Investor contact"}],"products":["Axiomer™","Editing Oligonucleotides","EONs"],"companies":[{"name":"Allen Overy Shearman Sterling LLP","relationship":"meeting venue"},{"name":"LifeSci Advisors","relationship":"investor relations firm"},{"name":"ProQR Therapeutics N.V.","ticker":"PRQR"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T14:11:00.303Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small/mid-cap","eventGravity":"routine_annual_meeting","householdBrandBoost":false}},"durationMs":21698,"modelName":"glm-4.7"}}